The American Journal of Medicine
Volume 121, Issue 9 , Pages 781-788.e1 , September 2008

Serum Total Bilirubin Level, Prevalent Stroke, and Stroke Outcomes: NHANES 1999–2004

This work was presented as an abstract at the Society of Vascular Medicine and Biology annual meeting, Baltimore, Maryland, June 2007.

  • Todd S. Perlstein, MD

      Affiliations

    • Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • Corresponding Author InformationRequests for reprints should be addressed to Todd S. Perlstein, MD, Division of Cardiovascular Medicine, Brigham and Women's Hospital, 75 Francis Street, A322, Boston, MA 02115
    • ,
  • Reena L. Pande, MD

      Affiliations

    • Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • ,
  • Mark A. Creager, MD

      Affiliations

    • Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass
    • ,
  • Jennifer Weuve, ScD

      Affiliations

    • Department of Environmental Health, Harvard School of Public Health, Boston, Mass
    • ,
  • Joshua A. Beckman, MD

      Affiliations

    • Department of Medicine, Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, Mass

References 

  1. Sacco RL, Adams R, Albers G, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a statement for healthcare professionals from the American Heart Association/American Stroke Association Council on Stroke: co-sponsored by the Council on Cardiovascular Radiology and Intervention: the American Academy of Neurology affirms the value of this guideline. Circulation. 2006;113:e409–e449
  2. Kawamura K, Ishikawa K, Wada Y, et al. Bilirubin from heme oxygenase-1 attenuates vascular endothelial activation and dysfunction. Arterioscler Thromb Vasc Biol. 2005;25:155–160
  3. Baranano DE, Rao M, Ferris CD, Snyder SH. Biliverdin reductase: a major physiologic cytoprotectant. Proc Natl Acad Sci U S A. 2002;99:16093–16098
  4. Stocker R, Yamamoto Y, McDonagh AF, et al. Bilirubin is an antioxidant of possible physiological importance. Science. 1987;235:1043–1046
  5. Ishikawa K, Navab M, Leitinger N, et al. Induction of heme oxygenase-1 inhibits the monocyte transmigration induced by mildly oxidized LDL. J Clin Invest. 1997;100:1209–1216
  6. True AL, Olive M, Boehm M, et al. Heme oxygenase-1 deficiency accelerates formation of arterial thrombosis through oxidative damage to the endothelium, which is rescued by inhaled carbon monoxide. Circ Res. 2007;101:893–901
  7. Ishizaka N, Ishizaka Y, Takahashi E, et al. High serum bilirubin level is inversely associated with the presence of carotid plaque. Stroke. 2001;32:580–583
  8. Dore S, Sampei K, Goto S, et al. Heme oxygenase-2 is neuroprotective in cerebral ischemia. Mol Med. 1999;5:656–663
  9. National Center for Health Statistics. National Health and Nutrition Examination Survey 03-04 (SP Questionnaire Component: Physical Functioning Questionnaire Data). Hyattsville, MD: National Center for Health Statistics; 2005;http://www.cdc.gov/nchs/data/nhanes/nhanes_03_04/pfq_c.pdfAccessed February 15, 2007
  10. Perlstein TS, Pande RL, Beckman JA, Creager MA. Serum total bilirubin level and prevalent lower-extremity peripheral arterial disease: National Health and Nutrition Examination Survey (NHANES) 1999 to 2004. Arterioscler Thromb Vasc Biol. 2008;28:166–172
  11. Pearson TA, Mensah GA, Alexander RW, et al. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation. 2003;107:499–511
  12. Gopinathan V, Miller NJ, Milner AD, Rice-Evans CA. Bilirubin and ascorbate antioxidant activity in neonatal plasma. FEBS Lett. 1994;349:197–200
  13. Durante W. Carbon monoxide and bile pigments: surprising mediators of vascular function. Vasc Med. 2002;7:195–202
  14. Erdogan D, Gullu H, Yildirim E, et al. Low serum bilirubin levels are independently and inversely related to impaired flow-mediated vasodilation and increased carotid intima-media thickness in both men and women. Atherosclerosis. 2006;184:431–437
  15. Lindenblatt N, Bordel R, Schareck W, et al. Vascular heme oxygenase-1 induction suppresses microvascular thrombus formation in vivo. Arterioscler Thromb Vasc Biol. 2004;24:601–606
  16. Panahian N, Yoshiura M, Maines MD. Overexpression of heme oxygenase-1 is neuroprotective in a model of permanent middle cerebral artery occlusion in transgenic mice. J Neurochem. 1999;72:1187–1203
  17. Panahian N, Huang T, Maines MD. Enhanced neuronal expression of the oxidoreductase—biliverdin reductase—after permanent focal cerebral ischemia. Brain Res. 1999;850:1–13
  18. Leinonen JS, Ahonen JP, Lonnrot K, et al. Low plasma antioxidant activity is associated with high lesion volume and neurological impairment in stroke. Stroke. 2000;31:33–39
  19. Novotny L, Vitek L. Inverse relationship between serum bilirubin and atherosclerosis in men: a meta-analysis of published studies. Exp Biol Med (Maywood). 2003;228:568–571
  20. Lin JP, O'Donnell CJ, Schwaiger JP, et al. Association between the UGT1A1*28 allele, bilirubin levels, and coronary heart disease in the Framingham Heart Study. Circulation. 2006;114:1476–1481
  21. Simpson CF, Boyd CM, Carlson MC, et al. Agreement between self-report of disease diagnoses and medical record validation in disabled older women: factors that modify agreement. J Am Geriatr Soc. 2004;52:123–127
  22. Berge E, Fjaertoft H, Indredavik B, Sandset PM. Validity and reliability of simple questions in assessing short- and long-term outcome in Norwegian stroke patients. Cerebrovasc Dis. 2001;11:305–310
  23. Van Hoydonck PG, Schouten EG, Temme EH. Reproducibility of blood markers of oxidative status and endothelial function in healthy individuals. Clin Chem. 2003;49:963–965
  24. Wu TW, Fung KP, Wu J, et al. Antioxidation of human low density lipoprotein by unconjugated and conjugated bilirubins. Biochem Pharmacol. 1996;51:859–862
  25. Breimer LH, Wannamethee G, Ebrahim S, Shaper AG. Serum bilirubin and risk of ischemic heart disease in middle-aged British men. Clin Chem. 1995;41:1504–1508
  26. Troughton JA, Woodside JV, Young IS, et al. Bilirubin and coronary heart disease risk in the Prospective Epidemiological Study of Myocardial Infarction (PRIME). Eur J Cardiovasc Prev Rehabil. 2007;14:79–84
  27. Stocker R, Perrella MA. Heme oxygenase-1: a novel drug target for atherosclerotic diseases?. Circulation. 2006;114:2178–2189
  28. McCarty MF. “Iatrogenic Gilbert syndrome”—a strategy for reducing vascular and cancer risk by increasing plasma unconjugated bilirubin. Med Hypotheses. 2007;69:974–994

 Dr Perlstein was supported by the National Heart, Lung and Blood Institute (NHLBI) Training Grant T32 HL07604 and an American College of Cardiology Foundation/Merck Research Fellowship Award. Dr Beckman was supported by American Diabetes Association Career Development Award 1-06-CD-01. Dr Creager is the Simon C. Fireman Scholar in Cardiovascular Medicine. Dr Pande was supported by NHLBI training grant T32 HL07604 and by a Research Career Development Award (K12 HL083786) from the NHLBI. Dr Weuve is partially supported by National Institutes of Environmental Health Sciences R01ES005257. This work also was supported by NHLBI grant R01 HL075771.

PII: S0002-9343(08)00470-1

doi: 10.1016/j.amjmed.2008.03.045

The American Journal of Medicine
Volume 121, Issue 9 , Pages 781-788.e1 , September 2008

Article Tools

* Image Usage & Resolution